

Interaction effects of significant risk factors on low bone mineral density in ankylosing spondylitis

Wenting Sun^{1,*}, Wenjun Mu^{2,*}, Caroline Jefferies³, Thomas Learch⁴, Mariko Ishimori³, Juan Wu², Zeran Yan^{5,6}, Nan Zhang^{5,6}, Qingwen Tao^{5,6}, Weiping Kong^{5,6}, Xiaoping Yan^{5,6} and Michael H. Weisman⁷

¹ China Academy of Chinese Medical Sciences, Beijing, China

² Beijing University of Chinese Medicine, Beijing, China

³ Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, United States of America

⁴ Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, United States of America

⁵ Beijing Key Lab for Immune-Mediated Inflammatory Diseases, China-Japan Friendship Hospital, Beijing, China

⁶ Department of TCM Rheumatology, China-Japan Friendship Hospital, Beijing, China

⁷ Stanford University, Stanford, California, United States of America

* These authors contributed equally to this work.

ABSTRACT

Background: To analyze individually and interactively critical risk factors, which are closely related to low bone mineral density (BMD) in patient with ankylosing spondylitis (AS).

Methods: A total of 249 AS patients who visited China-Japan Friendship Hospital were included in this training set. Patients with questionnaire data, blood samples, X-rays, and BMD were collected. Logistic regression analysis was employed to identify key risk factors for low BMD in different sites, and predictive accuracy was improved by incorporating the selected significant risk factors into the baseline model, which was then validated using a validation set. The interaction between risk factors was analyzed, and predictive nomograms for low BMD in different sites were established.

Results: There were 113 patients with normal BMD, and 136 patients with low BMD. AS patients with hip involvement are more likely to have low BMD in the total hip, whereas those without hip involvement are more prone to low BMD in the lumbar spine. Chest expansion, mSASSS, radiographic average grade of the sacroiliac joint, and hip involvement were significantly associated with low BMD of the femoral neck and total hip. Syndesmophytes, hip involvement and higher radiographic average grade of the sacroiliac joint increases the risk of low BMD of the femoral neck and total hip in an additive manner. Finally, a prediction model was constructed to predict the risk of low BMD in total hip and femoral neck.

Conclusions: This study identified hip involvement was strongly associated with low BMD of the total hip in AS patients. Furthermore, the risk of low BMD of the femoral neck and total hip was found to increase in an additive manner with the presence of syndesmophytes, hip involvement, and severe sacroiliitis. This finding may help rheumatologists to identify AS patients who are at a high risk of developing low BMD and prompt early intervention to prevent fractures.

Submitted 11 May 2023
Accepted 21 October 2023
Published 22 November 2023

Corresponding author
Weiping Kong, kwptgzy@163.com

Academic editor
Feng Pan

Additional Information and
Declarations can be found on
page 14

DOI 10.7717/peerj.16448

© Copyright
2023 Sun et al.

Distributed under
Creative Commons CC-BY 4.0

OPEN ACCESS

Subjects Epidemiology, Orthopedics, Rheumatology

Keywords Risk factor, Low bone mineral density, Ankylosing spondylitis, Interaction effect, Hip involvement, Femoral neck, Total hip, Prediction model, Syndesmophytes, Sacroiliitis

INTRODUCTION

Ankylosing spondylitis (AS) is a chronic inflammatory disease that primarily affects the axial skeleton (Mauro et al., 2021; Klavdianou, Tsiami & Baraliakos, 2021). The main feature of the disease is new bone formation, including syndesmosis, syndesmophytes formation, fusion of the sacroiliac joints, and ankylosis of the spine (Hwang, Ridley & Reveille, 2021). Low bone mineral density (BMD) is considered to be one of the most common complications in AS, which occurs in a range of 19% to 62% of patients undergoing screening (van der Weijden et al., 2012; Hinze & Louie, 2016; Klingberg et al., 2012; Ramírez et al., 2018). However, due to the relatively subtle symptoms of low BMD for AS patients, early detection is not easily achievable. Many physicians are unaware of the increased risk of low BMD in AS, which undoubtedly contributes to delayed diagnosis and increased fracture risk.

The risk factors and pathophysiology mechanism on low BMD in AS patient are unclear. Previous studies have shown that inflammation, disease course, disease activity, the release of inflammatory cytokines, mechanical factors, radiological damage may be related to low BMD in AS patients (Malochet et al., 2017; Kim et al., 2022; Bautista-Aguilar et al., 2021). To date, the risk factors of low BMD at different sites remain controversial. For example, Kaya et al. (2009) reported that as the disease progressed, BMD decreased in the femoral neck but increased in the lumbar spine. However, Wu et al. (2021) reported that lumbar BMD was not related to the course of AS. The most compelling reason for the apparent observed inconsistencies may be the complex course, over time, of low BMD in AS, which is unlikely to be solely influenced by one single predictor. Currently, there is no adequate explanation for the common risk factors for low BMD at different sites or for established interactive relationships among these risk factors.

The objectives of this study were to analyze individually and interactively critical risk factors, which are closely related to low BMD in patient with AS, and establish a nomogram prediction model to guide AS patients in preventing the occurrence of low BMD.

MATERIALS AND METHODS

Research subjects

A total of 249 patients from July 2012 to November 2018 recruited at the China-Japan Friendship Hospital were used as the training set. Another independently cohort including 140 patients from March 2019 to August 2022 were used as the validation set. This study employs continuous enrollment to mitigate selection bias. In this research, all included patients met the modified New York criteria for AS (Van der Linden, Valkenburg & Cats, 1984). Exclusion criteria: (1) the patient had undergone hip replacement surgery; (2) Suffering from other autoimmune diseases, including but not limited to inflammatory

bowel disease, psoriasis, ichthyosis, *etc*; (3) The patient has serious basic diseases, such as severe malnutrition, liver and kidney failure, *etc*; (4) The patient did not agree to participate in this study. All patients included in this study were evaluated by doctors to see if they met the inclusion criteria and signed the informed consent. The study has been reviewed and approved by ethics committees, including the research ethics committee of China-Japan Friendship Hospital (approval No. 2017-67) and the ethics committee of cedar Sinai Medical Center (approval No. pro00048849), and was conducted in accordance with the declaration of Helsinki.

Data collection/measurements

The questionnaires were administered by investigators with experience in epidemiological research. Patients' individual data, including gender, age, body mass index (BMI), current medication status, smoking, alcohol-related conditions, family history, onset age, and sports activities, were collected. The functional status, disease activity and severity in patients with AS were obtained by filling in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis Functional Index (BASFI) questionnaires (Zochling, 2011).

All patients were evaluated by the same rheumatologist. The evaluation scope included physical examination, modified-Schober score, chest expansion score, and the Bath Ankylosing Spondylitis Metrology Index (BASMI) (Calin *et al.*, 1994; Song *et al.*, 2009; Jenkinson *et al.*, 1994). The visual analog scale (VAS, 0–10cm) was used to assess the night pain and the patient global assessment (PGA) (Sieper *et al.*, 2009).

The New York classification criteria was used to grade the degree of sacroiliac joint, and the classification criteria were normal (0) to most serious (4). The diagnosis of AS was unilateral grade 3, unilateral grade 4 or bilateral grade 2 (Van der Linden, Valkenburg & Cats, 1984). A lateral radiograph of the cervical, thoracic and lumbar spine were collected, and the modified ankylosing spondylitis score (mSASSS) was used to evaluate the AS-related changes. The scoring standard of mSASSS are as follow the previously published study (van der Heijde *et al.*, 2019). The mSASSS was scored by a musculoskeletal radiologist and a cross-trained rheumatologist. Cohen's kappa coefficient was used to analyze the consistency of the two doctors' scores on the study subjects. When Cohen's kappa (κ) coefficients were >0.85 , it indicates that the consistency between researchers is good.

Hip involvement was evaluated by an experienced rheumatologist, including restricted range of motion, pain and Bath Ankylosing Spondylitis Radiology Hip Index (BASRI-hip). The BASRI-hip scoring method was refer to previous published study (Konsta *et al.*, 2023). Radiographic hip joint involvement was defined by at least 1 score in the BASRI-hip scoring system (MacKay *et al.*, 2000).

The disease activity score (ASDAS) for ankylosis was calculated using the formula in order to better assess the patient's disease activity (Deodhar *et al.*, 2022). The calculation of ASDAS-CRP refers to previous literature (Ørnbjerg *et al.*, 2022). To evaluate the disease activity, the disease activity score (ASDAS) of ankylosis was calculated using the

ASDAS-CRP formula, and the use of formula refers to published literature ([Zochling, 2011](#)).

At the time of patient enrollment, blood samples from AS patients were collected and analyzed using standard laboratory techniques, and BMD was measured. Before serum samples were collected, patients fasted overnight (at least 8 h). Indicators reflecting inflammation, including ESR and CRP, were collected. Other laboratory indicators closely related to AS, such as HLA-B27, were also recorded. BMD (g/cm²) was measured using dual-energy X-ray absorptiometry (DXA). The detection range of BMD includes: lumbar spine (L1-L4), femoral neck, and total hip. In this study, patients with a measured bone density T-scores < -1 at either site were defined as low BMD ([Cabrera et al., 2018](#)). In addition, the low BMD group was also divided into osteoporosis and osteopenia. Osteopenia and osteoporosis are defined according to the World Health Organization standards ([Kanis, 1994](#)).

Statistical analysis

Continuous variables are represented using the median, range, and/or mean, along with the standard deviation (SD) where appropriate. Categorical variables are presented as frequencies or percentages. To ensure data integrity, we endeavor to employ mean or median imputation whenever possible to address potential data missing issues. In cases of relatively symmetrical data distributions without conspicuous outliers, we typically opt for mean imputation. Conversely, when data distributions exhibit pronounced skewness or contain outliers, we are inclined to utilize median imputation. To assess differences between groups, appropriate statistical tests such as the chi-square test, t-test, and rank sum test were employed. The correlation coefficient was calculated using Spearman analysis. Logistic regression analysis was performed to identify significant risk factors associated with low BMD, both before and after adjusting for confounding factors. The effect sizes are reported as odds ratios (ORs) with corresponding 95% confidence intervals (CIs). We select variables based on the results of logistic regression and clinical relevance, ensuring that the inclusion of each feature is a reasonable explanation, and establish predictive model based on these variables. A nomogram for low BMD across different sites was developed, and its accuracy was evaluated using the concordance index. Akaike information criterion (AIC), Bayesian information criterion (BIC), and likelihood ratio (LR) test are used for model calibration, while net reclassification improvement (NRI), integrated discrimination improvement (IDI), and area under the receiver operating characteristic (AUROC) are employed for model discrimination. Clinical utility is assessed using decision curve analysis (DCA), and the model is further validated using validation set data. All statistical analyses were carried out using STATA software, special edition (version 14.0, STATA Corp, TX). The nomogram was constructed using the R language (version 3.5.2). By calculating the variance inflation factor (VIF), we determine whether there is collinearity among the factors. A VIF below 10 indicates no significant collinearity and can be used to create a nomogram ([Cheng et al., 2022](#)). The nomogram associates each variable with its corresponding score, and the sum of scores for all variables is defined as the total score. By drawing a vertical line from the axis of the total score, the

Table 1 Baseline characteristics of the training set.

Variables	All (N = 249)	Normal BMD (N = 132)	Low BMD (N = 117)	P value
Demographic variables				
Male	194 (77.9%)	98 (74.2%)	96 (82.1%)	0.138
Age, years	33.7 (10.5)	34.3 (10.4)	33.1 (10.6)	0.348
BMI, kg/m ²	23.1 (3.2)	23.4 (3.0)	22.7 (3.4)	0.044
Sport	38 (15.4%)	20 (15.2%)	18 (15.4%)	0.959
Family history	55 (21.1%)	31 (23.5%)	24 (20.5%)	0.573
Diagnosis duration, years	6.3 (5.0)	5.8 (4.8)	6.8 (5.2)	0.164
Symptoms duration, years	10.0 (6.7)	9.7 (6.9)	10.2 (6.5)	0.291
Onset age, years	23.8 (9.9)	24.6 (9.7)	22.9 (10.1)	0.106
Smoking index	48.6 (139.7)	46.8 (149.1)	50.6 (128.6)	0.462
Smoke duration, years	3.1 (6.8)	2.8 (6.14)	3.5 (7.5)	0.468
Cigarettes per day	3.5 (7.3)	3.3 (7.7)	3.6 (6.8)	0.389
Ever smoking	65 (26.1%)	31 (23.5%)	34 (29.1%)	0.317
Current smoking	62 (24.9%)	29 (22.0%)	33 (28.2%)	0.256
Alcohol duration	3.0 (6.8)	3.1 (6.8)	2.9 (6.9)	0.701
Alcohol history	50 (20.1%)	26 (19.7%)	24 (20.5%)	0.873
Daily alcohol	55 (22.1%)	29 (22.0%)	26 (22.2%)	0.962
Alcohol frequency	0.3 (0.8)	0.3 (0.7)	0.3 (0.8)	0.939
Current medication status				
Patients on TNF inhibitor	8 (3.2%)	3 (2.3%)	5 (4.3%)	0.372
Patients on NSAIDs	137 (55.0%)	71 (53.8%)	66 (56.4%)	0.678
Patients on cDMARDs	54 (21.7%)	23 (17.4%)	31 (26.5%)	0.083

Note:

BMD, bone mineral density; BMI, body mass index; TNF, tumour necrosis factor; cDMARDs, conventional DMARDs.

estimated probability of occurrence can be obtained. Statistical significance was considered at a threshold of $P < 0.05$.

RESULTS

Patient characteristics

A total of 249 patients from the training set participated in this study, including 194 males and 55 females. The average age was 34 ± 11 years, the onset age was 24 ± 10 years, and the diagnostic duration was 6 ± 5 years. Among them, 132 patients (53.0%) had normal BMD, and 117 patients (47.0%) had low BMD. BMI was significantly different between the normal BMD group and the low BMD group ($P < 0.05$), while other baseline characteristics were similar (all $P > 0.05$). The characteristics of study patients in the training set are presented in Table 1.

The disease-related variables and BMD of the study patients are summarized in Table 2. BASMI, chest expansion, radiographic average grade of the sacroiliac joint, hip involvement, and ASDAS-CRP showed a significant difference between the normal BMD

Table 2 Disease-related variables and bone mineral density of the training set.

Variables	All (N = 249)	Normal BMD (N = 132)	Low BMD (N = 117)	P value
Disease-related variables				
BASDAI, score	3.1 (1.3)	3.0 (1.2)	3.3 (1.4)	0.134
BASFI, score	1.4 (1.6)	1.4 (1.5)	1.5 (1.7)	0.565
BASMI, score	1.9 (2.0)	1.7 (2.0)	2.2 (2.0)	0.027
Night pain, score	4.0 (2.0)	3.8 (1.9)	4.2 (2.0)	0.104
PGA, score	3.9 (2.0)	3.8 (2.0)	4.1 (1.9)	0.275
Chest expansion, cm	4.4 (2.0)	4.7 (1.8)	4.1 (2.1)	0.030
modified-Schober, score	5.0 (1.9)	5.2 (1.8)	4.8 (1.9)	0.083
HLA-B27 Positive	223 (89.6%)	117 (88.6%)	106 (90.6%)	0.613
Sacroiliitis average, score	3.0 (0.8)	2.8 (0.8)	3.2 (0.8)	<0.001
mSASSS, score	13.2 (20.6)	11.1 (19.7)	14.9 (21.2)	0.142
Hip involvement	78 (38.4%)	35 (31.3%)	43 (47.3%)	0.020
ESR, mm/h	21.0 (19.7)	19.0 (18.9)	23.3 (19.6)	0.051
CRP, mg/L	1.6 (1.9)	1.6 (2.0)	1.7 (1.9)	0.142
ASDAS-CRP, scores	1.7 (0.7)	1.6 (0.7)	1.8 (0.8)	0.032
BMD				
Lumbar spine	1.1 (0.19)	1.2 (0.17)	1.0 (0.16)	<0.001
Femoral neck	0.9 (0.15)	1.0 (0.11)	0.8 (0.14)	<0.001
Total hip	0.9 (0.17)	1.0 (0.14)	0.8 (0.14)	<0.001

Note:

BMD, bone mineral density; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BASFI, Bath Ankylosing Spondylitis Functional Index; PGA, patient global assessment; HLA-B27, human leucocyte antigen B27; mSASSS, modified ankylosing spondylitis score; Sacroiliitis average, means average radiological grade of the sacroiliac joint.

and the low BMD groups (all $P < 0.05$). The baseline characteristics and disease-related variables in validation set were shown in [Table S1](#).

Prevalence of low BMD in different sites

Among all patients in the training set with low BMD, included 105 patients (89.7%) had osteopenia and 12 patients (10.3%) had osteoporosis. The prevalence of low BMD in different sites is shown in [Table S2](#). The lumbar spine was the most common site for low BMD (29.3%), followed by the femoral neck (26.5%) and total hip (24.9%). For patients with hip involvement, the total hip was the most common site for low BMD (34.5%). For patients without hip involvement, the lumbar spine was the most common site for low BMD (16.7%).

The association of BMD and mSASSS in AS patients with syndesmophytes

For AS patients in training set with syndesmophytes, increase in mSASSS was significantly associated with higher anteroposterior lumbar spine BMD ($r_s = 0.201$, $P = 0.024$) but not with femoral neck or total hip BMD ($r_s = -0.156$, $P = 0.081$; $r_s = -0.146$, $P = 0.102$, respectively) ([Table S3](#)).

Identification of risk factors for low BMD in the femoral neck and total hip

We further studied the effect-size estimates of multiple examined factors in association with the risk of low BMD before and after adjusting for confounding factors for femoral neck and total hip BMD (Table 3). Based on univariate logistic regression analysis several factors associated with the development of low BMD in the femoral neck and total hip were found at a significance level of 5% (Table S4). After adjusting for age and gender, statistical significance was still existed in all factors. After multivariate adjustment, chest expansion, BASMI, mSASSS, BMI, average radiographic grades at the sacroiliac joint and hip involvement were recognized as risk factors for low BMD of the femoral neck ($P < 0.05$). Chest expansion, BASFI, mSASSS, ASDAS-CRP, diagnosis duration, BMI, night pain, average radiographic grades at the sacroiliac joint, PGA, and hip involvement were recognized as risk factors for low BMD of the total hip ($P < 0.05$).

Prediction accuracy assessment

Basic and full models were constructed to evaluate the predictive performance of important factors associated with low BMD (Table 4). The full model included all the variables investigated, however, the basic model included all variables except for the significant risk factors identified by regression analyses. Calibration and discriminant statistics were applied to evaluate the prediction performance of the femoral neck and total hip significance factors which were added in the basic model. The prediction accuracy of the full model was significantly higher than that of the basic model. As shown by the comprehensive discriminant improvement, there were significant differences between the two models in predicting the performance of low BMD in the femoral neck and total hip ($P < 0.001$). For both the femoral neck and total hip, decision curve analysis suggested that our full model had superiority over the basic model for the fact that more clinical net benefits were obtained in a rather wide range of threshold probabilities when using full models than those when using the basic model (Fig. 1).

We applied the model to the validation set comprising 140 patients. The results demonstrated that the full model achieved an AUROC of 0.79 in the femoral neck prediction model and an AUROC of 0.80 in the total hip prediction model. The predictive performance of the validation set in Table S5.

Interaction explorations

Since the occurrence of low BMD in AS patients is a complex process, the influence of any risk factor may be small when evaluated alone, but it may be more obvious when other risk factors are combined. To obtain more accurate information, combined with the outcomes of clinical and logistic regression analysis, we divided the variables that were relevant for the low BMD into groups and further explored the risk factors affecting low BMD in the femoral neck and total hip (Table 5).

Hip involvement, mSASSS, and the average radiographic grade of the sacroiliac joint were found to be significant risk factors associated with low BMD in the femoral neck and total hip. When the average radiological grade of the sacroiliac joint exceeds grade 3 or hip

Table 3 Risk prediction for low BMD in AS patients.

Variables	Femoral neck			Total hip		
	OR	95% CI	P	OR	95% CI	P
Unadjusted						
Chest expansion	0.81	[0.70–0.94]	0.005	0.86	[0.74–0.99]	0.038
BASMI	1.21	[1.05–1.39]	0.007	1.17	[1.01–1.34]	0.032
BASFI	1.04	[0.88–1.24]	0.640	1.15	[0.98–1.36]	0.095
Total mSASSS	1.02	[1.01–1.03]	0.003	1.02	[1.00–1.03]	0.011
ASDAS-CRP	1.22	[0.84–1.78]	0.286	1.45	[0.99–2.12]	0.057
Diagnosis duration	1.04	[0.99–1.10]	0.157	1.07	[1.01–1.13]	0.019
BMI	0.92	[0.84–1.00]	0.054	0.88	[0.80–0.97]	0.010
Night pain	0.96	[0.83–1.11]	0.598	1.16	[1.00–1.34]	0.048
PGA	1.03	[0.90–1.19]	0.662	1.16	[1.01–1.35]	0.041
Sacroiliitis average	2.08	[1.44–3.02]	<0.001	1.90	[1.31–2.75]	0.001
Hip involvement	2.08	[1.55–5.20]	0.001	2.90	[1.55–5.43]	0.001
Age and gender adjusted						
Chest expansion	0.82	[0.71–0.95]	0.008	0.85	[0.73–0.99]	0.031
BASMI	1.20	[1.04–1.38]	0.013	1.18	[1.02–1.37]	0.025
BASFI	1.03	[0.87–1.22]	0.729	1.15	[0.97–1.36]	0.099
Total mSASSS	1.02	[1.00–1.03]	0.016	1.02	[1.01–1.04]	0.009
ASDAS-CRP	1.25	[0.86–1.82]	0.245	1.47	[1.00–2.16]	0.051
Diagnosis duration	1.03	[0.97–1.09]	0.293	1.07	[1.01–1.14]	0.017
BMI	0.90	[0.82–0.99]	0.026	0.88	[0.80–0.97]	0.008
Night pain	0.97	[0.84–1.12]	0.692	1.16	[1.01–1.35]	0.041
PGA	1.05	[0.91–1.21]	0.547	1.17	[1.01–1.35]	0.036
Sacroiliitis average	2.20	[1.49–3.24]	<0.001	2.03	[1.38–2.99]	<0.001
Hip involvement	2.88	[1.48–5.59]	0.002	3.05	[1.61–5.79]	0.001
Multivariable adjusted						
Chest expansion	0.79	[0.67–0.93]	0.005	0.81	[0.69–0.95]	0.011
BASMI	1.18	[1.01–1.38]	0.035	1.16	[0.99–1.36]	0.060
BASFI	1.08	[0.89–1.31]	0.424	1.22	[1.01–1.47]	0.044
Total mSASSS	1.02	[1.00–1.04]	0.016	1.02	[1.00–1.04]	0.014
ASDAS-CRP	1.38	[0.91–2.09]	0.133	1.62	[1.06–2.48]	0.027
Diagnosis duration	1.04	[0.98–1.11]	0.166	1.07	[1.00–1.14]	0.038
BMI	0.87	[0.78–0.97]	0.009	0.87	[0.79–0.97]	0.012
Night pain	1.01	[0.86–1.18]	0.946	1.21	[1.03–1.42]	0.018
PGA	1.09	[0.93–1.27]	0.278	1.22	[1.04–1.43]	0.016
Sacroiliitis average	2.09	[1.38–3.17]	0.001	2.01	[1.32–3.05]	0.001
Hip involvement	2.83	[1.38–5.82]	0.004	2.77	[1.33–5.76]	0.006

Note:

BASMI, Bath Ankylosing Spondylitis Metrology Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BMI, body mass index; PGA, patient global assessment. OR, odds ratio; 95% CI, 95% confidence interval. Sacroiliitis average, means average radiological grade of the sacroiliac joint. *P* values were calculated before and after adjusting for age, gender, HLA-B27, smoking index, smoking duration, cigarettes per day, current smoking, alcohol history and alcohol duration. In multivariable adjusted model, risk prediction of each adjusted factor was calculated by adjusting for the other factors.

Table 4 Prediction accuracy gained by adding the identified significant factors for low BMD in training set.

Statistic	Femoral neck		Total hip	
	Basic model	Full model	Basic model	Full model
Calibration				
AIC	302	226	286	213
BIC	395	333	366	320
LR test (χ^2)	Ref.	20.93	Ref.	25.11
LR test (<i>P</i> value)	Ref.	0.002	Ref.	<0.001
Discrimination				
NRI (<i>P</i> value)	Ref.	0.013	Ref.	0.022
IDI (<i>P</i> value)	Ref.	<0.001	Ref.	<0.001
AUROC	0.62	0.74	0.62	0.77
AUROC (<i>P</i> value)	0.003		0.002	

Note:

AIC, Akaike information criterion; BIC, Bayesian information criterion; LR, likelihood ratio; NRI, net reclassification improvement; IDI, integrated discrimination improvement; AUROC, area under the receiver operating characteristic; Ref., reference.




Figure 1 Net benefits gained by the significant factors identified for low BMD in AS patients in decision curve analysis at two different sites. (A) Femoral neck; (B) total hip. [Full-size !\[\]\(b75b336f46a04702a9641299e986c074_img.jpg\) DOI: 10.7717/peerj.16448/fig-1](https://doi.org/10.7717/peerj.16448/fig-1)

involvement, the presence of syndesmophytes (defined as at least one vertebral corner mSASSS score ≥ 2 (*van der Heijde et al., 2019*)) further increased the risk of low BMD in the femoral neck and total hip (both $P < 0.05$).

Notably, hip involvement not only interacted with the presence of syndesmophytes but also with the average radiological grade of the sacroiliac joint. When the average radiological grade of the sacroiliac joint exceeds grade 3, hip involvement increased the risk

Table 5 The interaction of three significant factors identified for low BMD of the femoral neck and total hip in AS patients.

Interaction items	Femoral neck			Total hip		
	OR	95% CI	P	OR	95% CI	P
No syndesmophytes/Sacroiliitis average ≤ 3	Ref.			Ref.		
No syndesmophytes/Sacroiliitis average > 3	1.40	[0.51–3.81]	0.513	3.68	[1.34–10.12]	0.012
Syndesmophytes present/Sacroiliitis average ≤ 3	0.43	[0.10–1.79]	0.243	1.11	[0.29–4.20]	0.883
Syndesmophytes present/Sacroiliitis average > 3	2.29	[1.02–5.15]	0.045	3.35	[1.37–8.18]	0.008
No syndesmophytes/Hip involvement = 0	Ref.			Ref.		
No syndesmophytes/Hip involvement = 1	2.22	[0.70–7.01]	0.174	4.74	[1.48–15.20]	0.009
Syndesmophytes present/Hip involvement = 0	1.14	[0.40–3.20]	0.809	1.92	[0.64–5.77]	0.244
Syndesmophytes present/Hip involvement = 1	3.51	[1.33–9.30]	0.012	3.55	[1.21–10.36]	0.021
Sacroiliitis average ≤ 3 /Hip involvement = 0	Ref.			Ref.		
Sacroiliitis average ≤ 3 /Hip involvement = 1	1.33	[0.24–7.46]	0.746	4.43	[0.97–20.22]	0.055
Sacroiliitis average > 3 /Hip involvement = 0	1.31	[0.48–3.57]	0.596	2.57	[0.88–7.56]	0.086
Sacroiliitis average > 3 /Hip involvement = 1	3.73	[1.48–9.39]	0.005	4.78	[1.71–13.37]	0.003

Note:

OR, odds ratio; 95% CI, 95% confidence interval; Ref., reference; Sacroiliitis average, means average radiological grade of the sacroiliac joint; Syndesmophytes present, defined as at least one vertebral corner mSASSS score ≥ 2 .

of low BMD in the femoral neck and total hip (both $P < 0.05$). This finding implies that for AS patients with hip involvement, the combination of severe sacroiliitis or syndesmophytes significantly increase the risk of low BMD at the femoral neck and total hip.

Prediction model

Finally, a nomogram was constructed to predict the risk of low BMD in AS patients based on significant factors that were identified in the femoral neck and total hip (Fig. 2). Nomogram's important factors were analyzed by positive logistic regression at a significance level of 5%. For a specific patient, each indicator has specific values, mapped onto the "Points" scale to obtain individual scores per indicator. Summing all scores gives a total. Locate this total on the "Total Points" and map to the "Risk" scale to determine patient low BMD risk. For example, assuming a female (20 points) AS patient with an onset age of 20 (10 points), BMI of 18 (82 points), BASFI of 5 (64 points), chest expansion of 3 (30 points), sacroiliitis average of four scores (10 points), mSASSS scores of 18 (10 points) and hip involvement (50 points), the possibility of low BMD of total hip was estimated to be 70%.

DISCUSSION

Low BMD is the most common comorbidity of AS due to multiple factors that disrupt bone metabolic balance. It increased fracture risk in AS patients, therefore, identifying risk factors is of great importance for the prevention of low BMD. The main purpose of this study is to investigate individually and interactively critical risk factors for low BMD in AS patients at different sites and to establish predictive nomogram models reflecting the data from our subjects. To our knowledge, this is the first study to predict the risk factors for




Figure 2 Risk prediction nomograms for low BMD in AS patients at two different sites. (A) Femoral neck; (B) total hip. BMI, body mass index; BASFI, Bath Ankylosing Spondylitis Functional Index; mSASSS, modified ankylosing spondylitis score; Sacroilitis average, means average radiological grade of the sacroiliac joint. [Full-size !\[\]\(ba1b80118482ccef74a5d718ca4d7242_img.jpg\) DOI: 10.7717/peerj.16448/fig-2](https://doi.org/10.7717/peerj.16448/fig-2)

low BMD in different sites based on an interaction analysis and nomogram prediction model. Our interaction analyses revealed that low BMD could be caused by the superposition of risk factors. Our interaction analyses revealed that multiple factors that disrupt bone metabolism balance increase the risk of low BMD in an additive manner. Identifying these risk factors for low BMD in AS patients will prompt early intervention to prevent fractures.

Currently, it is still a controversial topic about the common sites of low BMD in AS patients ([Klingberg et al., 2012](#); [Singh et al., 1995](#); [Wang et al., 2017](#); [Cai et al., 2020](#); [Deminger et al., 2017](#)). [Deminger et al. \(2017\)](#) found that low BMD was more common at the proximal femur compared to the lumbar spine (16.5% vs. 6.3%) in AS patients. However, [Klingberg et al. \(2012\)](#) suggested that the lumbar spine is the most common sites of low bone mass in AS patients. Unfortunately, these studies did not discuss the differences in the sites prone to low BMD between patients with and without hip involvement. Our study found that the total hip was the most common site of low BMD (34.5%) in patients with hip involvement, while the lumbar spine is the most common site of low BMD (16.7%) in patients without hip involvement. This suggested that inflammation of the hip and the resulting limitation of activity may accelerate the loss of hip BMD. Furthermore, the impact of osteophytes on bone density is also noteworthy, especially concerning lumbar spine BMD. [Kaya et al. \(2009\)](#) in a follow-up of 55 AS patients after 1 year, found that 3.4% of patients had an increase in lumbar spine BMD. It is believed that osteophytes have an effect on the measurement of anterior and posterior lumbar spine bone density, which was further corroborated by our study. For AS patients with osteophytes, the increase in mSASSS is significantly correlated with higher anterior and posterior lumbar spine BMD. Therefore, clinicians should take note that for patients with osteophytes, it is unreasonable to assess the extent of bone loss based solely on BMD measurements in the anterior and posterior lumbar spine positions.

Since predictors may have different effects on BMD at different sites, we explored potential risk factors for low BMD at the femoral neck and total hip separately. To avoid the potential effect of syndesmophytes on the measurement of BMD at the anteroposterior lumbar spine, we did not explore risk factors for low BMD at the lumbar spine. Our results revealed that chest expansion, mSASSS, BMI, the average radiographic grade of the sacroiliac joint, and hip involvement were the common risk factors of the femoral neck and total hip. These findings also confirm some previous studies. For example, the relationship between mSASSS and low BMD has also been explored in different literatures. [Karberg et al. \(2005\)](#) demonstrated that mSASSS score was significantly associated with low BMD, especially in the femoral neck. Another study also showed that low BMD was significantly associated with the development of new syndesmophytes ([Kim et al., 2018](#)). Based on the above results, it could be confirmed that AS patients with high mSASSS scores caused limited activity, which might accelerate the process of low BMD.

In addition, we found that more severe sacroiliitis was also a risk factor for low BMD in the femoral neck and total hip. In previous studies, it was also documented that low trabecular bone score in AS patients was associated with the severity of sacroiliitis ([Kang et al., 2018](#)). This may be related to trabecular bone loss as a result of chronic

inflammation, and its impact on BMD is manifested in a non-single site. Therefore, aggressive interventions in the progressive stages of AS (especially for more severe sacroiliitis) should effectively prevent low BMD by increasing the mobility associated with pain relief and potentially having a direct anti-inflammatory effect on bone ([Wang et al., 2017](#)). Furthermore, we found that hip involvement was a common risk factor for low BMD in the femoral neck and total hip. This result was supported by Wang et al, who found that hip involvement was one of the risk factors for developing bone loss in AS patients ([Wang et al., 2015](#); [Liu et al., 2021](#)). On the one hand, the relationship between hip involvement and low BMD could be explained by local inflammation in the hip joint. On the other hand, for AS patients with hip involvement, early pain and late hip ankylosis would decrease the patient's activity, which would further aggravate bone loss.

Although the impact of each risk factor is small when the risk factors are evaluated separately, the impact is more obvious when there is a superposition of other risk factors. However, most of the current studies tend to focus on individual risk factors, while ignoring the interaction between other factors. To extend the outcomes reported by published studies, we explored the interaction between each risk factor and observed synergistic effects. Our results showed that the presence of syndesmophytes significantly increased the risk of low BMD in the femoral neck and total hip when the radiological average grade of the sacroiliac joint exceeded grade 3 or hip involvement was present. Notably, hip involvement not only interacted with syndesmophytes but also with the radiographic grade of the sacroiliac joint, highlighting the importance of severe sacroiliitis, syndesmophytes, and hip involvement in the development of low BMD. These results underscore the need to closely monitor AS patients with severe radiological damage, hip involvement, and higher sacroiliitis grades to prevent the occurrence of low BMD.

Taken together, through the analysis of the survey data, we explored the risk factors of low BMD in different sites in AS patients. More importantly, we found that some risk factors may act on the susceptibility of low BMD in a cumulative way. Finally, to facilitate the practical application of our findings, we created a risk prediction nomogram model for the occurrence of low BMD at different sites for AS patients, which revealed reasonable prediction accuracy. We hope that this study provides background data that can be used to further explore the potential risk factors of low BMD in AS patients, including individual and interaction effects, and further explore the risk factors of low BMD in AS patients for the process of early detection and prevention.

There are some limitations in this study. Due to our limited sample size, the conclusions are not definitive and therefore it is necessary to formulate corresponding standards according to different ages and gender. It is also necessary, for the future, to adopt quantitative computed tomography to avoid the interference of actual density in AS patients with syndesmophytes to draw more accurate conclusions ([Deminger et al., 2022](#)). Currently, the use of this model relies on certain radiological examination and measurement indicators. Despite these parameters being part of routine examinations, there is still room for further enhancement in the convenience of applying this model. Furthermore, there is literature mentioning the beneficial effects of TNF- α inhibitors on BMD ([Haroon et al., 2014](#)). Unfortunately, in this study, there were only eight cases of

patients treated with TNF- α therapy in the training set, which resulted in the inability to observe the impact of TNF inhibitors on BMD. The major strength of the present study is the finding that AS patients with hip involvement are more likely to experience low BMD in the total hip, whereas those without hip involvement are more prone to low BMD in the lumbar spine. We also identified several risk factors associated with low BMD in the femoral neck and total hips, including syndesmophytes, hip involvement, and radiological average grade of the sacroiliac joint. Importantly, we found that these factors increase the risk of low BMD in an additive manner. Finally, we established an effective prediction model in order to facilitate new research into the possibility of creating a prevention strategy.

CONCLUSION

Low BMD was most likely to occur in the total hip in patients with hip involvement and in the lumbar spine in patients without hip involvement. This study identified syndesmophytes, hip involvement and severe sacroiliitis increases the risk of low BMD in an additive manner and established a nomogram prediction model to help rheumatologists identify high risk patients to prevent low BMD.

ACKNOWLEDGEMENTS

We thank the patients from the Department of TCM rheumatology, China-Japan Friendship Hospital for providing support to this study, the participants of cedars Sinai Medical Center for their guidance and assistance with this study, and all the investigators who contributed to this study.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding

The study received funding from the National High Level Hospital Clinical Research Funding (No. 2022-NHLHCRF-LX-02-0104), the National Science Foundation of Beijing, China (No. 7182148) the Beijing Traditional Chinese Medicine Science and Technology Development Fund Project (No. JJ-2020-87) and the Spondylitis Association of America. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures

The following grant information was disclosed by the authors:

National High Level Hospital Clinical Research Funding: 2022-NHLHCRF-LX-02-0104.

National Science Foundation of Beijing, China: 7182148.

Beijing Traditional Chinese Medicine Science and Technology Development Fund: JJ-2020-87.

Spondylitis Association of America.

Competing Interests

The authors declare that they have no competing interests.

Author Contributions

- Wenting Sun conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Wenjun Mu conceived and designed the experiments, performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Caroline Jefferies performed the experiments, prepared figures and/or tables, and approved the final draft.
- Thomas Learch analyzed the data, prepared figures and/or tables, and approved the final draft.
- Mariko Ishimori analyzed the data, prepared figures and/or tables, and approved the final draft.
- Juan Wu performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Zeran Yan performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Nan Zhang performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.
- Qingwen Tao performed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Weiping Kong conceived and designed the experiments, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.
- Xiaoping Yan conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.
- Michael H. Weisman conceived and designed the experiments, authored or reviewed drafts of the article, and approved the final draft.

Human Ethics

The following information was supplied relating to ethical approvals (*i.e.*, approving body and any reference numbers):

The research ethics committee of China-Japan Friendship Hospital (approval No. 2017-67) and the ethics committee of Cedar Sinai Medical Center (approval No. pro00048849).

Data Availability

The following information was supplied regarding data availability:

The raw measurements are available in the [Supplemental File](#).

Supplemental Information

Supplemental information for this article can be found online at <http://dx.doi.org/10.7717/peerj.16448#supplemental-information>.

REFERENCES

Bautista-Aguilar L, López-Medina C, Ladehesa-Pineda I, Ábalos-Aguilera MDC, Ruiz-Vilchez D, Garrido-Castro JL, Gómez-García I, Puche-Larrubia MÁ, Salmoral-Chamizo A,

- Collantes-Estévez E, Escudero-Contreras A, Font-Ugalde P. 2021. Prevalence and associated factors of low bone mineral density in the femoral neck and total hip in axial Spondyloarthritis: data from the CASTRO cohort. *Journal of Clinical Medicine* 10(12):2664 DOI 10.3390/jcm10122664.
- Cabrera D, Kruger M, Wolber FM, Roy NC, Totman JJ, Henry CJ, Cameron-Smith D, Fraser K. 2018. Association of plasma lipids and polar metabolites with low bone mineral density in singaporean-chinese menopausal women: a pilot study. *International Journal of Environmental Research and Public Health* 15(5):1045 DOI 10.3390/ijerph15051045.
- Cai PL, Yan YY, Wei W, Chen XS, Zhao J, Zhang ZK, Zhang P. 2020. The bone mineral density of hip joint was reduced in the initial stage of ankylosing spondylitis? *Medicine* 99:e19132 DOI 10.1097/MD.00000000000019132.
- Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T. 1994. A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index. *Journal of Rheumatology* 21:2281–2285.
- Cheng J, Sun J, Yao K, Xu M, Cao Y. 2022. A variable selection method based on mutual information and variance inflation factor. *Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy* 268(1):120652 DOI 10.1016/j.saa.2021.120652.
- Deminger A, Klingberg E, Lorentzon M, Geijer M, Göthlin J, Hedberg M, Rehnberg E, Carlsten H, Jacobsson LT, Forsblad-d’Elia H. 2017. Which measuring site in ankylosing spondylitis is best to detect bone loss and what predicts the decline: results from a 5-year prospective study. *Arthritis Research & Therapy* 19(1):273 DOI 10.1186/s13075-017-1480-0.
- Deminger A, Klingberg E, Lorentzon M, Hedberg M, Carlsten H, Jacobsson LTH, Forsblad-d’Elia H. 2022. Factors associated with changes in volumetric bone mineral density and cortical area in men with ankylosing spondylitis: a 5-year prospective study using HRpQCT. *Osteoporosis International* 33(1):205–216 DOI 10.1007/s00198-021-06049-4.
- Deodhar A, van der Heijde D, Sieper J, Van den Bosch F, Maksymowych WP, Kim TH, Kishimoto M, Ostor A, Combe B, Sui Y, Chu AD, Song IH. 2022. Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. *Arthritis & Rheumatology* 74(1):70–80 DOI 10.1002/art.41911.
- Haroon NN, Sriganthan J, Al Ghanim N, Inman RD, Cheung AM. 2014. Effect of TNF-alpha inhibitor treatment on bone mineral density in patients with ankylosing spondylitis: a systematic review and meta-analysis. *Seminars in Arthritis and Rheumatism* 44(2):155–161 DOI 10.1016/j.semarthrit.2014.05.008.
- Hinze AM, Louie GH. 2016. Osteoporosis management in ankylosing spondylitis. *Current Treatment Options in Rheumatology* 2(4):271–282 DOI 10.1007/s40674-016-0055-6.
- Hwang MC, Ridley L, Reveille JD. 2021. Ankylosing spondylitis risk factors: a systematic literature review. *Clinical Rheumatology* 40(8):3079–3093 DOI 10.1007/s10067-021-05679-7.
- Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. 1994. Defining spinal mobility in ankylosing spondylitis. The bath AS metrology index. *Journal of Rheumatology* 21:1694–1698.
- Kang KY, Chung MK, Kim HN, Hong YS, Ju JH, Park SH. 2018. Severity of sacroiliitis and erythrocyte sedimentation rate are associated with a low trabecular bone score in young male patients with ankylosing spondylitis. *Journal of Rheumatology* 45(3):349–356 DOI 10.3899/jrheum.170079.

- Kanis JA. 1994.** Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO study group. *Osteoporosis International* 4(6):368–381 DOI 10.1007/BF01622200.
- Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. 2005.** Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes. *Journal of Rheumatology* 32:1290–1298.
- Kaya A, Ozgocmen S, Kamanli A, Ardicoglu O. 2009.** Bone loss in ankylosing spondylitis: does syndesmophyte formation have an influence on bone density changes? *Medical Principles and Practice* 18(6):470–476 DOI 10.1159/000235897.
- Kim HR, Hong YS, Park SH, Ju JH, Kang KY. 2018.** Low bone mineral density predicts the formation of new syndesmophytes in patients with axial spondyloarthritis. *Arthritis Research & Therapy* 20(1):231 DOI 10.1186/s13075-018-1731-8.
- Kim JW, Park S, Jung JY, Kim HA, Kwon SR, Choi ST, Kim SS, Kim SH, Suh CH. 2022.** Prevalence and factors of osteoporosis and high risk of osteoporotic fracture in patients with ankylosing spondylitis: a multicenter comparative study of bone mineral density and the fracture risk assessment tool. *Journal of Clinical Medicine* 11(10):2830 DOI 10.3390/jcm11102830.
- Klavdianou K, Tsiami S, Baraliakos X. 2021.** New developments in ankylosing spondylitis-status in 2021. *Rheumatology* 24:vi29–vi37 DOI 10.1093/rheumatology/keab523.
- Klingberg E, Lorentzon M, Mellström D, Geijer M, Göthlin J, Hilme E, Hedberg M, Carlsten H, Forsblad-d’Elia H. 2012.** Osteoporosis in ankylosing spondylitis prevalence, risk factors and methods of assessment. *Arthritis Research & Therapy* 14(3):R108 DOI 10.1186/ar3833.
- Konsta M, Nurmohamed MT, Iliopoulos A, Sfrikakis PP, van Denderen JC, Visman I, Sakelariou GT, van der Horst-Bruinsma IE. 2023.** Prevalence and radiographic progression of hip involvement in patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors. *Journal of Rheumatology* 50:342–350 DOI 10.3899/jrheum.220061.
- Liu W, Song H, Man S, Li H, Zhang L. 2021.** Analysis of bone strength and bone turnover markers in ankylosing spondylitis with radiological hip involvement. *Medical Science Monitor* 27:e932992 DOI 10.12659/MSM.932992.
- MacKay K, Brophy S, Mack C, Doran M, Calin A. 2000.** The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. *Journal of Rheumatology* 27:2866–2872.
- Malochet GS, Pereira B, Tatar Z, Tournadre A, Moltó A, Dougados M, Soubrier M. 2017.** Prevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures. *BMC Musculoskeletal Disord* 18(1):357 DOI 10.1186/s12891-017-1718-7.
- Mauro D, Thomas R, Guggino G, Lories R, Brown MA, Ciccia F. 2021.** Ankylosing spondylitis: an autoimmune or autoinflammatory disease? *Nature Reviews Rheumatology* 17(7):387–404 DOI 10.1038/s41584-021-00625-y.
- Ørnbjerg LM, Linde L, Georgiadis S, Rasmussen SH, Lindström U, Askling J, Michelsen B, Giuseppe DD, Wallman JK, Pavelka K, Závada J, Nissen MJ, Jones GT, Relas H, Pirilä L, Tomšič M, Rotar Z, Geirsson AJ, Gudbjornsson B, Kristianslund EK, Hetland ML. 2022.** Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: data from the EuroSpA collaboration. *Seminars in Arthritis and Rheumatism* 56:152081 DOI 10.1016/j.semarthrit.2022.152081.
- Ramírez J, Nieto-González JC, Curbelo Rodríguez R, Castañeda S, Carmona L. 2018.** Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: a systematic review and meta-analysis. *Seminars in Arthritis and Rheumatism* 48(1):44–52 DOI 10.1016/j.semarthrit.2017.12.001.

- Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, Dougados M, Hermann KG, Landewé R, Maksymowych W, van der Heijde D. 2009. The assessment of spondyloarthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. *Annals of the Rheumatic Diseases* 68(Suppl 2):ii1–ii44 DOI 10.1136/ard.2008.104018.
- Singh A, Bronson W, Walker SE, Allen SH. 1995. Relative value of femoral and lumbar bone mineral density assessments in patients with ankylosing spondylitis. *Southern Medical Journal* 88(9):939–943 DOI 10.1097/00007611-199509000-00010.
- Song IH, Rudwaleit M, Listing J, Sieper J. 2009. Comparison of the bath ankylosing spondylitis disease activity index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations. *Annals of the Rheumatic Diseases* 68(11):1701–1707 DOI 10.1136/ard.2008.099226.
- van der Heijde D, Braun J, Deodhar A, Baraliakos X, Landewé R, Richards HB, Porter B, Readie A. 2019. Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis. *Rheumatology* 58(3):388–400 DOI 10.1093/rheumatology/key128.
- Van der Linden S, Valkenburg HA, Cats A. 1984. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis and Rheumatism* 27(4):361–368 DOI 10.1002/art.1780270401.
- van der Weijden MA, Claushuis TA, Nazari T, Lems WF, Dijkmans BA, van der HI. 2012. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. *Clinical Rheumatology* 31(11):1529–1535 DOI 10.1007/s10067-012-2018-0.
- Wang D, Hou Z, Gong Y, Chen S, Lin L, Xiao Z. 2017. Bone edema on magnetic resonance imaging is highly associated with low bone mineral density in patients with ankylosing spondylitis. *PLOS ONE* 12(12):e0189569 DOI 10.1371/journal.pone.0189569.
- Wang DM, Zeng QY, Chen SB, Gong Y, Hou ZD, Xiao ZY. 2015. Prevalence and risk factors of osteoporosis in patients with ankylosing spondylitis: a 5-year follow-up study of 504 cases. *Clinical and Experimental Rheumatology* 33:465–470.
- Wu X, Zhong JY, Wang G, Xu HJ. 2021. Factors relating to bone mineral density in young and middleaged patients with ankylosing spondylitis. *Chinese Medical Journal* 134(21):2556–2563 DOI 10.1097/CM9.0000000000001787.
- Zochling J. 2011. Measures of symptoms and disease status in ankylosing spondylitis: ankylosing spondylitis disease activity score (ASDAS), ankylosing spondylitis quality of life scale (ASQoL), bath ankylosing spondylitis disease activity index (BASDAI), bath ankylosing spondylitis functional index (BASFI), bath ankylosing spondylitis global score (BAS-G), bath ankylosing spondylitis metrology index (BASMI), dougados functional index (DFI), and health assessment questionnaire for the spondylarthropathies (HAQ-S). *Arthritis Care & Research* 63(S11):S47–S58 DOI 10.1002/acr.20575.